Paratek Pharmaceuticals (PRTK) Expects to Present Omadacycline Phase 1b Data in Q416
Tweet Send to a Friend
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced that it projects its ongoing phase 1b clinical study evaluating omadacycline in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE